Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access To Approved Therapies As Company Enters New Geographies
Published by The Street By Business Wire Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its third annual Patient Access Philosophy Report. This report is designed to measure Alnylam’s global progress against its 2017 commitments to